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Effect of iron status on the intestinal absorption of aluminum: A
reappraisal. Clinical and experimental studies have shown that serum
aluminum (Al) is bound to transferrin and that cellular uptake of Al
appears to be mediated by transferrin receptors. Based on these findings
it is widely believed that intestinal Al absorption occurs via iron-specific,
transferrin-dependent pathways and that iron (Fe) deficiency increases the
intestinal absorption of Al. However, since no transferrin receptors are
expressed on the absorptive surface of small intestinal epithelial cells this
notion is doubtful. To further clarify the issue the present study investi-
gated the effect of marked alterations of body Fe stores on the intestinal
absorption of Al using three different rat models. (1) Serum Al concen-
trations and urinary excretion rates of Al were measured in iron-
overloaded (Fe+) or iron-deficient (Fe—) rats with either normal (C) or
impaired (5/6 nephrectomy) renal function (Nx) employing oral Al loads
in single dose studies. (II) Tissue Al accumulation as well as serum and
urine Al were determined in respective experimental groups exposed to a
prolonged (41 days) dietary Al load. (III) To assess the effect of Fe status
on the intestinal absorption of Al directly at the organ level perfusions of
in situ rat gut preparations were performed. In the single dose studies
administration of Al resulted in similar urinary excretion rates of Al in
intact kidney groups (C+Fe—, 229 85 nmol/5 days; C+Fe+, 240 59
nmol/5 days) despite marked differences in liver Fe (C+Fe—, 1.34 0.16
vs. C+Fe+, 55.69 13.20 JLmol/g) and duodenal mucosal Fe (C+Fe—,
0.68 0.11 vs. C+Fe+, 3.17 0.82 rmol/g). In addition, mucosal Al
concentration 24 hours after the load was not affected by the Fe status
(C+Fe—, 37 16 nmol/g, C+Fe+, 56 19 nmol/g). Regardless of the Fe
status post-load Al excretion was enhanced in Nx rats (Nx+Fe—, 533
234 nmol/five days, Nx+Fe+, 536 201 nmol/five days). Irrespective of
Fe status a prolonged dietary Al load resulted in a similar increase in
tissue Al concentration (nmol/g) in liver (baseline, 159 22; C+Fe—,
276 125; C+Fe+, 251 71; Nx+Fe—, 330 119; Nx+Fe+, 437 67)
and in hone (baseline, 219 119; C+Fe—, 433 174, C+Fe+, 485 141;
Nx+Fe—, 504 185; Nx+Fe+, 548 215). The increase in spleen Al was
significantly larger in Fe-overloaded rats (baseline, 194 20; C+Fe+,
511 129 vs. C+Fe—, 308 62, P < 0.05; Nx+Fe+, 514 67 vs.
Nx+Fe—, 389 119, P < 0.05). Brain Al tended to rise in Nx rats only
(baseline, 96 33; Nx+Fe+, 174 100, Nx+Fe—, 156 78, P = NS).
Analogous results were obtained in in situ intestinal perfusion studies: Fe
deficiency and Fe overload both did not affect the time-dependent
increase in serum Al in either systemic or portal vein blood. When
paracellular intestinal permeability was assessed mannitol absorption was
significantly higher in uremic animals as compared to controls. Pharma-
cological blockade (2 mvi kinetin) of the paracellular permeability sub-
stantially reduced the time-dependent increase in serum Al in uremic rats
but had little effect in control animals, suggesting that even the excess
absorption of Al observed in uremia occurs via a paracellular rather than
an iron-specific pathway. In conclusion, the findings of the present study
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provide several lines of evidence against the commonly accepted view that
the intestinal absorption of Al occurs via iron-specific pathways. Most
likely, this is related to the fact, that neither the absorption of Fe nor the
absorption of Al are mediated via transferrin receptors. In addition, the
enhanced intestinal absorption of Al observed in uremic rats does also not
occur via iron-specific pathways, but seems to be due to increased
paraccllular permeability of the intestine.
Aluminum intoxication in patients with chronic renal failure is
commonly related either to the use of aluminum-contaminated
dialysis fluids or to the ingestion of aluminum-containing phos-
phate-binding drugs [1]. Avoidance of aluminum-contaminated
water in the dialysis process as well as preferred prescription of
aluminum-free phosphate binders have greatly diminished the
prevalence of aluminum-related diseases. Bone biopsy-based
studies have shown that the prevalence of aluminum-related bone
disease may now range from a recent 27% [2, 31 to values below
3% [4—6], and thus to be considerably lower than reported in
earlier studies [7, 81. However, some degree of aluminum accu-
mulation resulting in subtle or overt toxicity may persist in a
certain number of dialysis patients. This finding is largely related
to intestinal absorption from low doses of aluminum-containing
phosphate binders and from other dietary sources [3, 9—11]. In
addition, several episodes of acute and, in some instances, fatal
aluminum intoxication have alerted the medical community and
have drawn attention to the fact that aluminum toxicity will still
have to be considered in the future [12, 131. In this regard precise
delineation of conditions that may predispose to enhanced accu-
mulation or toxicity of aluminum will further facilitate monitoring
and treatment of patients at risk. With respect to intestinal
absorption, several factors such as citrate and other complexing
agents, young age and the uremic state itself have been shown to
increase the bioavailabilty and the intestinal absorption rate of
aluminum [9, 11, 14—17].
In particular, iron deficiency has been suggested to promote the
intestinal absorption of aluminum [18], and this latter finding
would be of general importance in view of the increasing preva-
lence of absolute or functional iron deficiency related to the
widespread use of human recombinant erythropoietin in patients
with chronic renal failure [19, 20]. Since serum aluminum is bound
to transferrin and since cellular uptake of aluminum is mediated
by transferrin receptors [21—231, it was felt that iron deficiency
might increase aluminum absorption via increased expression of
transferrin receptors [18, 24]. However, because no transferrin
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receptors are expressed on the absorptive surface of small intes-
tinal epithelial cells, this notion is doubtful [25—27]. Moreover, the
data base regarding the interrelationship between iron deficiency
and enhanced absorption of aluminum is scarce and little infor-
mation is available as to what degree other factors such as dietary
complexing constituents or the uremic status may affect the
increase in aluminum absorption in iron deficiency [11, 18,
28—33]. Therefore, the current study was undertaken to investi-
gate whether marked alterations of body iron stores would indeed
consistently affect the intestinal absorption of aluminum and, if so,
whether the presence of the uremic milieu might modulate this
effect. Three different experimental models were used to address
these questions: (a) single (lose studies with subsequent monitor-
ing of serum concentrations and urinary excretion rates of alumi-
num; (b) extended exposure to a large dietary aluminum load with
subsequent measurement of the tissue burden of aluminum in
various organs; and (c) in Situ intestinal perfusion studies. The
results strongly argue against the notion that iron deficiency
increases the fractional absorption of aluminum and they do not
suggest that iron overload may protect from intestinal aluminum
absorption.
Methods
Manipulation of renal function and of iron status
Male outbred Sprague-Dawley rats (Han:SPRD, Department
of Laboratory Animal Research, RWTH) weighing 180 to 220 g
were kept on a standard laboratory diet containing 200 mg/kg
(3.58 mmol/kg) iron (Fe), 0.80% calcium, and 0.75% phosphorus
supplemented with 400 U/kg vitamin D3 (Eggersmann, Rinteln,
Germany). To compensate for genetic differences all litter mates
were distributed equally among the test groups prior to the
experiments as described previously [341. Renal failure groups
were rendered uremic by a two-stage 5/6 nephrectomy (Nx) [15].
Two weeks after the second operation rats matched for weight
and residual renal function were allocated to 3 groups of 10 rats
each: Fe deficiency (Nx+Fe—), Fe overload (Nx+Fe+), and
unchanged Fe status (Nx). In parallel, rats with intact kidneys
were split into respective treatment groups (C+Fe—, C+Fe+,
and C). Subsequently, all animals had free access to distilled
water, but were pair-fed with specific diets: Fe deficiency was
produced by feeding a low Fe diet (6 mg [107 smol] Fe per kg) (C
1038; Altromin, Lage, Germany) for four weeks together with
removal of 12 ml blood. Two ml blood were drawn by tail vein
puncture on days 8, 12, 15, 19, 23, and 26. Fe loading was
accomplished by intramuscular injection of 1 ml Fe dextran
(Ferrum Hausmann, Asta Pharma, Frankfurt, Germany; 50 mg
[895 smol] Fe/mi) on days 8, 13, 16, 19, and 24 as well as feeding
the same diet supplemented with Fe [900 mg (16.1 mmol)/kg].
Uremic rats and controls with normal Fe status received a basic
feed containing 180 mg (3.2 mmol) Fe per kg but otherwise
identical with the low Fe diet (C 1000, Altromin). The efficacy of
Fe removal was ascertained by weekly determinations of hemo-
globin, red blood cell counts and erythrocyte indices. Subse-
quently, rats were studied either by oral or by intravenous
aluminum (Al) loads or by the intestinal perfusion technique.
For the long-term exposure study induction of Fe deficiency or
Fe overload followed the same protocol. During dietary exposure
to Al Fe overload and deficiency were maintained by weekly
intramuscular injections of 50 mg Fe and weekly removal of 2 ml
blood, respectively.
Upon termination of each experimental series nonheme Fe was
measured in liver tissue and duodenal mucosa of all animals: Rats
were anesthetized with ether and underwent median laparotomy.
Following cannulation of the abdominal aorta ligatures were
placed at the subdiaphragmatic portion and proximal to the aortic
bifurcation. A cold perfusion (4°C) with 0.9% NaCl was started at
a flow rate of 10 mi/mm and continued until mesenteric vessels
had become colorless and until the transected hepatic vein
showed a clear effluent. Thereafter, the liver and duodenum were
excised. The duodenum was opened, rinsed, and the mucosa was
then stripped from the serosa with a glass slide and the content of
nonheme Fe was determined in both tissues.
Single dose oral or intravenous aluminum loads
In all six study groups intestinal absorption of Al following a
single oral load was studied according to a well established
protocol [15, 17, 351. Seventy-two hours prior to Al ingestion rats
were placed in individual metabolic cages. Forty hours later, food
was withdrawn but access to deionized drinking water was per-
mitted until one hour prior to ingestion of Al. Each rat received
a single oral load of 407 imol (11 mg) Al administered as A1CI3
in 1 ml of deionized water by gastric lavage. For baseline urinary
excretion rates of Al 24-hour urine collections were obtained
twice, and following the Al load urine was collected for five days.
Water and food were returned two hours and 16 hours after
administration of Al, respectively. Post-load all rats were placed
on the Fe-deficient C 1038 diet to rule out pre-analytical errors
due to differences in diets. Fecal Al contamination of urine was
prevented by frequent and scrupulous cleaning of the metabolic
cages with deionized water (Al content <70 nmol/liter) and by
fasting the rats prior to and after the Al load.
In a separate series of experiments animals were dosed orally
with Al and blood was drawn at hours 0, 1, 5 and 24. An additional
series of experiments addressed the kinetics of mucosal Al in the
duodenum following an oral Al load in Fe-overloaded or Fe-
deficient animals. At hours 0, 5, and 24 duodena were prepared as
described above. Subsequently, to remove surface bound Al
preparations were washed three times with a citrate buffer (5 mrvi,
pH 7.4) according to a previously described method [36]. Tissue
Al was determined in mucosal pellets after the third wash.
To evaluate differences in tissue binding and renal handling of
Al related to changes in Fe status and/or renal function, a further
set of six experimental groups was studied employing intravenous
administration of Al. A slow i.v. injection of 370 nmol (10 sg) Al
(A1C13) in 0.5 ml deionized water was delivered over 10 minutes.
Thereafter, the respective groups were handled as outlined above
and recovery of Al in urine was monitored for five days.
In the final part of these experiments rats with normal renal
function and unaltered Fe status were studied with single oral
loads of 204 nmol (5.5 mg) Al administered as AlCl3 concurrent
with 204 nmol (11.4 mg) Fe (FeCl3) or an equimolar amount of
NaC1 adjusted to the same pH. Again, recovery of Al was
monitored in urine for a total of five days.
Long-term exposure to a dietary aluminum load
To further determine the effect of Fe status on the absorption
and compartmentalization of Al uremic rats were exposed to a
prolonged dietary Al load. Nx rats were either Fe-depleted or
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Fe-overloaded as described. Thereafter, these animals and respec-
tive uremic controls were pair-fed an Al-supplemented [8 g (296
mmol)/kg Al, AI(OH)3] low Fe [6mg (107 jimol)/kg] diet together
with drinking water containing 1250 mg/liter (46.3 mmol/liter) Al
(Al lactate) and 100 g/Iiter (292 mM) sucrose. To avoid changes in
Al bioavailability due to differences in the Fe content of the diet
all groups were fed the same low Fe diet. However, alteration of
Fe status was maintained by Fe injections or serial bleedings, and
at the end of the experiment Fe status was confirmed by measure-
ment of nonheme Fe in liver tissue and duodenal mucosa. After
41 days of exposure to this large dietary Al load rats were
transferred to individual metabolic cages. Food was withdrawn to
prevent fecal contamination of urine and distilled water (Al
content < 70 nmol/liter) was supplied as drinking water. Subse-
quently, a 24 hour urine was collected. After completion of the
collection period blood was obtained and the animals were
sacrificed to determine tissue Al concentrations of trabecular
bone, liver, spleen, brain, and muscle on day 42. An identical
protocol was carried out, separately, in rats with normal renal
function.
In situ intestinal perfusion
To assess the effect of Fe status on the intestinal absorption of
Al directly at the organ level perfusions of in situ rat gut
preparations were performed. Rats with normal renal function
and either Fe overload or Fe deficiency and pair-fed controls with
normal Fe status were fasted for 48 hours with free access to
drinking water. Following anesthesia with 45 mg/kg pentobarbital
the abdomen was opened by a midline incision and an afferent
silicone catheter (internal diameter 0.5 mm) was inserted into the
proximal jejunum 1 cm past the ligament of Treitz. The efferent
limb was a polyvinyl chloride cannula (length 8 cm, internal
diameter 3 mm) inserted proximal to the ileocecal juncture at the
insertion of the ileocecal ligament. A small intestinal segment of
approximately 100 cm length was perfused. Prior to perfusion the
intestine was returned to the peritoneal cavity and the abdomen
was closed with sutures. In experiments comparing uremic rats
with pair-fed controls ureters were ligated to prevent elimination
of absorbed Al. Perfusion experiments were performed in an air
temperature-controlled hood and the animals' body temperature
was kept at 37°C. During a 30-minute equilibration period the
intestinal segment was perfused at a rate of 1 mi/mm with an
Al-free solution containing 138 mivi NaCl, 4.5 mM KC1, 1.25 CaC12,
2.0 m glucose, and 2.5 m sodium lactate adjusted to pH 4.0.
Subsequently, Al absorption was studied during a 75-minute
absorption period using an equimolar perfusate solution contain-
ing 2.5 mi Al lactate. To assess water fluxes and permeability of
the paracellular intestinal pathway 200 mg/liter 3H-inulin (specific
radioactivity 0.075 mCi/g) and 1 mrvi 14C-mannitol (specific radio-
activity 1.5 mCi/mo!) were added to the solution in some experi-
ments during the equilibration period as well as during the
absorption period. To block the paracellular pathway additional
perfusions were carried Out using a solution containing 2 mxi
kinetin. All perfusate solutions were freshly prepared and were
kept at 37°C during the perfusion experiments. A totally occlusive
roller pump (Desaga, Heidelberg, Germany) was used to pump
the perfusate to the afferent catheter. Perfusion pressure was
continuously monitored and was kept well below 30 cm water.
Effluent perfusate was drained by gravity into polypropylene
collection tubes in a fraction collector (Redi Frac, Pharmacia
LKB, Uppsala, Sweden) in five minute intervals. Blood samples of
200 jsl were drawn via a cannula inserted into the right jugular
vein at the start of perfusion with Al-containing media and after
15, 30, 45, 60, and 75 minutes of the absorption period. In
addition, blood of the portal vein was collected at completion of
the absorption period (75 mm).
Analytical procedures
Aluminum in serum and urine was determined by flameless
atomic absorption spectrophotometry using a 2380 spectropho-
tometer equipped with a HGA-400 flameless furnace and an
AS-40 automatic sample injector (Perkin-Elmer) by a modifica-
tion [17] of a previously described method [15]. For Al determi-
nation in bone, tibiae were bisected and marrow was removed
with a jet of deionized water. Dried samples of cancellous bone
were ground to powder in an agate mill, defatted (petroleum
ether/ether, 1:1 vol:vol), digested with nitric acid (Suprapur;
Merck, Darmstadt, Germany; Al content < 148 nM), diluted with
distilled water and analyzed as reported earlier [37, 381. Similarly,
for Al determination in liver, spleen, brain, muscle, and duodenal
mucosa dried aliqotes were weighed, ground and analyzed follow-
ing digest with nitric acid. Muscle samples were defatted, redried
and reweighed prior to the digest [391.
Creatinine in serum was measured by an autoanalyzer (Syn-
chron Astra 4; Beckman, Fullerton, CA, USA). Red blood cell
count, hematocrit, hemoglobin, and erythrocyte indices were
measured by a multichannel autoanalyzer (Autolyzer 801; Con-
traves, Zurich, Switzerland).
For nonheme Fe determination tissues were dried (120°C, 16
hr) and ground to powder in an agate mill. Aliquotes (20 mg) were
digested with 150 iii of a 1:1 (vol:vol) mixture of concentrated
sulphuric and nitric acids by heating for 15 minutes over a low
flame [40]. After cooling to ambient temperature the colorless
residue was diluted with distilled water and its Fe content
determined photometrically using bathophenanthroline-disul-
fonic acid as color reagent (Merckotest; Merck).
Paracellular permeability was assessed by quantitation of 14C-
mannitol absorption using 3H-inulin as a non-absorbable marker.
From each collected five-minute fraction of the intestinal effluent
1 ml aliquotes were counted in a scintillation fluid (Hionic Fluor;
Packard, Downers Gove, IL, USA) using a 1215 Rackbeta II
(LKB, Uppsala, Sweden) scintillation counter. The absorption of
mannitol relative to inulin was calculated by standard equations
and was corrected for the length of the perfused intestinal
segment [41].
Aluminum lactate was purchased from Riedel-de Haën (Seelze,
Germany) and sodium lactate was supplied by Fluka (Buchs,
Switzerland). Kinetin was purchased from Serva (Heidelberg,
Germany), 3H-inulin and '4C-mannitol were supplied by Amer-
sham Buehler (Braunschweig, Germany). All other chemicals
were obtained from Merck.
Reported data are expressed as mean value I so except
where noted otherwise. Statistical probabilities are derived from
the Kruskal-Wallis test, a non-parametric analysis of variance,
followed by a sequentially rejective multiple test procedure to
compare specific groups [421. A value of P < 0.05 was considered
significant. Correlation between two parameters was accom-
plished by Spearman rank correlation.
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Table 1. Hematologic examinations, serum creatinine and iron (Fe) concentration in liver and duodenal mucosa in iron-depleted rats (Fe— ) and
iron-overloaded rats (Fe+) with either normal renal function (C) or chronic renal failure (Nx) and in appropriate controls (N = 25 per group)
Group
.
Hemoglobin
giliter
.Hematocrit
%
Erythrocytes
Tera/liter
.Creatinine
pinol/liter
Liver Fe Duodenal Fe
pinol/g
C 13.8 1.2 45.1 4.3 8.5 0.9 43 6 7.14 1.61 1.59 0.22
C+Fe— 6.4 0.9°" 27.4 2.6' 6.3 0.6° 45 4 1.34 0.16°" 0.68 0.11°'
C+Fe+ 13.7 0.6 45.0 1.3 8.3 0.3 41 6 55.69 13.20° 3.17 0.82'
Nx 8.3 2.2 37.6 10.3 6.0 1.6 124 430 10.03 1.74 1.30 0.27
Nx+Fe— 5.9 1.2°'' 29.4 5.0"" 5.1 0.6" 110 15° 1.30 0.25°" 0.59 0.25"
Nx+Fe+ 12.5 0.5° 57.0 2.4" 8.5 0.5° 112 13° 90.85 13.77" 4.66 0.98°
P < 0.05 vs. C; 'P <0.05 vs. C+Fe+; cp < 0.05 vs. Nx; "p < 0.01 vs. Nx+Fe+; "P <0.001 vs. all C groups.
Group
—_N
Urine Al nmol/day
Pre-load
Post-load
day 1
Post-load
total
excretion
(5 days)
C
C+Fe—
C+Fe+
Nx
Nx+Fe—
Nx+Fe+
10
9
10
7
8
9
5±3
4 1
7 4
17 6
9 2
8 4
141±43
82 27
102 38
232 152
267 135
273 156
316±65
229 85
240 59
500 185°°
533 234'°
536 201°°
°P< 0.01 v C; "P < 0.05 vs.C+Fe—; "P < 0.01 vs. C+Fe+
Results
Iron overloading and Fe depletion resulted in significant hema-
tologic changes both in rats with normal renal function and in
uremic rats (Table 1). Fe-depleted animals had significantly lower
hemoglobin concentrations, a lower erythrocyte count and lower
hematocrits as compared to their controls. In addition, changes in
body Fe stores were confirmed by significant increases or de-
creases in liver Fe concentration as well as in the nonheme Fe
concentration of duodenal mucosa. Baseline urinary excretion
rates of Al were not affected by Fe deficiency in comparison to
rats with normal Fe status or Fe-overloaded animals (Table 2).
Following a single oral dose of Al urinary Al excretion rates
increased several-fold in all study groups within the first post-load
day (Fig. 1). Changes in Fe status had no effect on the magnitude
of this increase regardless of renal function. However, indepen-
dent of changes in Fe status Al excretion tended to be greater in
uremics as compared to their respective controls. Therefore,
post-load total urinary excretion of Al over five days was signifi-
cantly larger in uremic rats versus control rats regardless of the Fe
status, and vice versa the Fe status had no effect on the post-load
total excretion of Al in either renal function group.
In analogy, measurement of serum Al concentrations showed a
similar pattern of post-load increases in all groups (Table 3).
Baseline fasting serum concentrations of Al were comparable
between all groups. One hour after ingestion of Al there was a
significant increase in serum Al concentrations, the magnitude of
which was again not affected by alterations in Fe status. In
contrast, irrespective of Fe status uremic rats had significantly
Serum Al concentration nM
Pre- Post-load Post-load Post-load
Group N load 1 hour 6 hours 24 hours
C 10 43 11 207 54' 661 170'°' 115 70
C+Fe— 10 40 4 204 130° 530 152°" 122 89
C+Fe+
Nx
10
10
45 12
41 11
248 63'
524 271d
481 126°"
667 159°
94 81
156 104
Nx+Fe— 10 41 12 433 485 181° 139 96
Nx+Fe+ 10 42 12 374 133 48
to their respective controls. Five hours after the oral Al load
serum Al was elevated in each group to a similar degree regardless
of renal function or Fe status. Twenty-four hour post-load serum
Attended to drop back to baseline values, but was still signifi-
cantly elevated in group Nx+Fe+, Prior to the oral load Al
concentrations in duodenal mucosa were higher in Nx rats as
compared to controls (Table 4). After five hours post-load
Table 2. Urinary excretion of aluminum (Al) in iron-depleted rats
(Fe—) and iron-overloaded rats (Fe+) with either normal renal
function (C) or chronic renal failure (Nx) and in appropriate controls
following an oral load of 407 /.Lmol aluminum
300
100
2
0
E
E
E
:3
a)C
Time, days
Fig. 1. Time course of the urinaly excretion of aluminum following a single
oral dose of 407 pmol aluminum in iron-overloaded uremic rats
(Nx+Fe+, —X—)and in iron-depleted uremic rats (Nx+Fe—;--•--) and in
respective controls (C+Fe+, —O——C+Fe—- --•--) (error bars omitted).
Table 3. Pre-load and post-load serum concentrations of aluminum
(Al) in iron-depleted rats (Fe—) and iron-overloaded rats (Fe+) with
either normal renal function (C) or chronic renal failure (Nx) and in
appropriate controls loaded with a single oral dose of 407
mol aluminum
3
'P < 0.05 vs. pre-load; "P < 0.05 vs. 1 hr post-toad; "P < 0.05 vs. C;
"P < 0.05 vs. C+Fe—; 0p < 0.05 vs. C+Fe+
higher post-load one-hour serum Al concentrations as compared mucosal Al was significantly elevated in all treatment groups. Fe
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Table 4. Aluminum (Al) concentrations in duodenal mucosa
subsequent to an oral load of 407 jxmol aluminum in iron-depleted rats
(Fe—) and iron-overloaded rats (Fe+) with either normal renal
function (C) or chronic renal failure (Nx) and in appropriate controls
Group N
Mucosal Al nmol/g
Pre-load
Post-load
5 hours
Post-load
24 hours
C
C+Fe—
C+Fe+
Nx
Nx+Fe—
Nx+Fe+
8
8
8
8
8
8
9 98 96 5
35 9""
29 8""33 8"
89 28"
109 18",'
108 47a,b
81 31'
94 37U
79 35a,h
48 17
37 16
56 19
92 34e_g
62 39"131 2l
a P < 0.05 vs. pre-load; b P < 0.05 vs. post-load 24 hr; P < 0.01 vs. C;d P < 0.05 vs. C+Fe—; c P <0.01 vs. C+Fe+; fp <0.05 vs. Nx+Fe—; sp
< 0.01 vs. Nx+Fe+
Table 5. Urinary excretion of aluminum (Al) subsequent to an
intravenous load of 370 nmol Al in iron-depleted rats (Fe—) and iron-
overloaded rats (Fe+) with either normal renal function (C) or chronic
renal failure (Nx) and in appropriate controls
Group N
Urine Al nmollday
Pre-load
Post-load
day 1
Post-load
total
excretion
(5 days)
C
C+Fe—
C+Fc+
Nx
Nx+Fe—
Nx+Fe+
10
9
10
7
8
9
10 2
7 1
10 2
14 7
15 5
13 3
210 37
186 81
168 16
170 57
116 42
76 30
287 47
249 77
250 15
267 67
209 39"
144 34''
ap < 0.01 vs. C; tP < 0.05 vs. C+Fe—, C+Fe+, Nx, Nx+Fe—
deficiency did not increase mucosal Al nor did Fe overload reduce
mucosal Al accumulation. Twenty-four hours after the load
mucosal Al was still significantly elevated in uremic rats and this
tissue burden of Al was most marked in Fe-overloaded animals. In
contrast, rats with normal renal function had lower mucosal Al,
however, again Fe-overloaded rats tended to have the highest
tissue burden of Al. Following an intravenous load of Al urinary
excretion of Al was similar among rats with normal renal function
(Table 5). Therefore, Fe status did not affect the total Al recovery
in urine in the control groups. In uremic rats, however, post-load
total excretion was significantly lower in group Nx+ Fe+ versus all
other groups. When Al was administered orally together with Fe
chloride to rats with normal renal function and with normal body
Fe stores, the post-load daily urinary Al excretion rates tended to
be larger in this group as compared to a control group given Al
together with sodium chloride (Table 6). Total post-load excretion
after five days was significantly larger in the group given Fe and Al
orally.
Long-tenn dietary exposure to aluminum
At the completion of the experimental period liver Fe and
duodenal Fe had changed to a similar degree in Fe deficiency and
Fe overload as compared to respective animals of the single dose
studies (data not shown). As compared to pre-load values serum
Al concentrations rose significantly in uremic rats and in controls
Table 6. Urinary excretion of aluminum (Al) in control rats (normal
renal function, normal body iron stores) following an oral load of either
204 nmol Al (AICI1) with 204 nmol NaCI or 204 nmol Al together with
204 nmol iron (Fe) (FeCI3]
Urine Al nmol/day
Post-load
total
Post-load excretion
Group N Pre-load day 1 (5 days)
Al+NaCI 8 4 4 58 38 87 52
Al+Fe 8 5 8 137 71 170 80"
"P < 0.05 vs. Al+NaCI
E
C
E
E
ci)
Cl)
Time, days
Fig. 2. Serumaluminum (Al) concentrations in iron-depleted rats (C+Fe—,
—X—) and iron-overloaded rats (C+Fe+, ---) with normal renal ftLnction(N = 10 per group) and in appropriate controls (C, —) after exposure to
Al-supplemented diet and Al-containing drinking water for 41 days (animals
were fasted for 24 hr prior to serum Al on day 42) (mean SE). Serum
aluminum concentrations at days 21 and 42 were significantly different
from respective baseline values (P < 0.001).
at day 21 (Figs. 2 and 3). This increase in serum Al was more
marked in uremic rats, but was not affected by changes in body Fe
stores. If anything, Fe-depleted rats tended to have slightly lower
values. At day 42, 24 hours after removal of Al-containing feed
and Al-containing drinking water serum Al concentrations had
dropped by 47% and 44% in controls and in uremic rats,
respectively. Again, neither this decline in serum Al nor absolute
values were affected by Fe status. The corresponding urinary Al
excretion rates revealed higher Al excretion in uremic rats as
compared to controls (Fig. 4). Neither Fe overload nor Fe
deficiency seemed to affect Al excretion subsequent to long-term
dietary exposure. Cumulative intake of Al with the drinking water
was similar among rats with a given renal function (C, 15.1 4.8;
C+Fe—, 14.6 6.1; C+Fe+, 13.9 5.6 mmol) but was higher in
Nx-rats (Nx, 24.5 9.0; Nx+Fe—, 26.1 8.7; Nx+Fe+, 23.8
5.2 mmol). On the contrary, total ingestion of food Al was lower
in uremic rats as compared to controls, but was not different
between the respective Fe-overloaded or Fe-deficient groups (Nx
181 43 vs. C 304 79 mmol, P < 0.01; Nx+Fe— 158 61 vs.
C+Fe— 334 44 mmol, P < 0.05; Nx+Fe+ 167 72 vs. C+Fe+
328 93 mmol, P < 0.01). Tissue Al concentrations tended to be
elevated in rats with normal renal function as compared to
Pre-load 21 42
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Fig. 3. Serum aluminum (Al) concentrations in iron-depleted rats
(Nx+Fe—, —X—) and iron-overloaded rats (Nx+Fe+, ---) with impaired
renal function (N = 10 per group) and in appropriate controls (Nx, —)
after exposure to Al-supplemented diet and Al-containing drinking water fur
41 days (animals were fasted fur 24 hr prior to serum A/on day 42) (mean
sr.). Serum aluminum concentrations at days 21 and 42 were significantly
different from respective baseline values (P < 0.001).
200
C C+Fe—C+Fe+ Nx Nx+Fe—Nx+Fe+
Fig. 4. (Irinaty aluminum (Al) excretion rates in iron-depleted rats (Fe—)
and iron-overloaded rats (Fe+) with either normal renal function (C) or
chronic renal failure (Nx) and in appropriate controls (N = 10 per group)
after exposure to Al-supplemented diet and Al-containing drinking water for
41 days (*P < 0.05 vs. C', C+Fe—, and C+Fe+).
baseline values. However, this increase attained significance only
in liver, spleen and bone (Table 7). The increase in tissue Al
concentrations followed a similar pattern in uremic groups (Table
8). Again, significant increments were observed in hone, liver, and
spleen. Irrespective of renal function, Fe deficiency did not seem
to increase the tissue Al burden as compared to Fe-overloaded
groups or to controls with normal Fe status. In particular, there
was no pronounced elevation of brain Al in Fe-deficient rats. The
increase in spleen Al was even significantly larger in Fe-over-
loaded rats as compared to group C+Fe—. Similarly, spleen Al
was highest in group Nx+Fe+ and was significantly different from
the post-load spleen Al in group Nx+Fe—.
In situ intcstinal perfusion studies
When rats with intact kidneys were perfused with an Al-
containing perfusate, a continuous time-dependent increase in
Table 7. Tissue aluminum (Al) concentrations (nmol/g) in iron (Fe)-
depleted rats (C+Fe—) and iron-overloaded rats (C + Fe+) with
normal renal function and in appropriate controls (C) after exposure to
Al-supplemented diet and Al-containing drinking water for 41 days
(N = 10 per group)
Group Liver Spleen Muscle Brain Bone
Baseline 159 22 194 20 48 4 104 37 219 119
C 328 121" 381 219" 81 11 130 59 433 130"
C+Fe—
C+Fe+
276 125"
251 71"
308 62"
511 l29"'
85 15
100 33
107 15
104 44
433
485
174"
141"
Table 8. Tissue aluminum (Al) concentrations (nmol/g) in iron (Fe)-
depleted rats (Nx+Fe—) and iron-overloaded rats (Nx+Fe+) with
impaired renal function and in appropriate controls (Nx) after exposure
to Al-supplemented diet and Al-containing drinking water for 41 days
(N = 10 per group)
Liver Spleen Muscle Brain Bone
Baseline 185 70 216 31 44 4 96 33 226 100
Nx 330 81" 407 163" 67 30 156 63 556 193"
Nx+Fe— 330 119" 389 119" 26 7 156 78 504 185"
Nx+Fe+
"P < 0.
437 67" 514 67"" 52 33 174 100 548 215"
05 vs. baseline; "P < 0.05 vs. Nx+Fe—
Time, minutes
Fig. 5. Serum aluminum (Al) concentrations in iron-depleted rats (C+Fe—,
—X—) and iron-overloaded rats (C+Fe+, --0--) with normal renalfunctiori
(N = 6 per group) and in appropriate controls (C,—) during in situ small
intestinal perfusion with an Al-containing perfusion solution over a period of
75 minutes [mean standard errorj. Serum aluminum concentrations at
minutes 30 to 75 were significantly different from respective baseline
values (P < 0.01).
serum Al concentrations was observed (Fig. 5). After 30 minutes
of perfusion there was a parallel increase in serum Al concentra-
tions in all three groups. Systemic peak serum Al concentrations
after 75 minutes of exposure did not differ among the three
experimental groups and compared well with the respective Al
concentrations in portal vein blood (C, 2685 489 vs. 4133 948
flM, P < 0.01; C+Fe—, 2770 756 vs. 4555 1427 riM, P = NS;
C+Fe+, 2763 933 vs. 4067 837 mvi, P < 0.05). When
paracellular permeability was assessed, control rats absorbed very
little mannitol from the perfused intestinal segment relative to
inulin throughout the 75 minutes of perfusion with the standard
"P < 0.05 vs. baseline; "P < 0.05 vs. C+Fe—
Time, days
Group
*
*
0
E
E
C
E
Ca
a)C
150
100
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solution (16.7 20.5 p.1/hr/cm, N = 7), and this finding was not
affected by differences in Fe status. In contrast, mannitol absorp-
tion was significantly higher in uremic animals as compared to the
controls (64.5 34.5 p.1/hr/cm, P < 0.01, N = 7). In a subsequent
experiment, control rats with unaltered Fe status and pair-fed
uremic animals were perfused with either standard solution or a
perfusion solution containing kinetin (Fig. 6). In rats with intact
kidneys the addition of kinetin had no marked affect on the
time-dependent increase in serum Al concentrations. At variance,
uremic rats perfused with kinetin showed a divergent pattern.
Kinetin caused a progressively smaller increase in serum Al
concentrations in comparison to uremic rats treated under stan-
dard perfusion conditions. Although the increase in serum Al was
lower in the Nx+kinetin group, the slope of the time-dependent
increase in serum Al was still steeper than the slope in control
rats, and serum Al concentrations were significantly higher after
45, 60, and 75 minutes.
Discussion
Aluminum and iron share several physicochemical properties,
and recent studies have shown that intense interrelationships exist
between the metabolism of both elements. In serum the predom-
inant fraction of aluminum is non-ultrafiltrable and largely bound
to transferrin [22, 23]. There is ample experimental evidence that
transferrin mediates not only serum transport but also cellular
uptake and toxicity of aluminum. Therefore, cellular uptake of
transferrin-hound aluminum via transferrin receptors on cell
surfaces and via subsequent internalization by receptor-mediated
endocytosis has been shown in a variety of cell lines, namely
neuroblastoma cells, erythroleukemia cells, hematopoietic pro-
genitor cells, osteosarcoma cells, hepatocytes, and lymphocytes
[24, 43—47J. Intracellularly, aluminum may interfere with iron
metabolism at several, less well defined sites including ferritin
regulation by iron, utilization of iron for the synthesis of hem, and
expression of the transferrin receptor [21, 48].
In addition, it is now also widely believed that aluminum
absorption occurs via iron-specific, transferrin-dependent path-
ways and that iron deficiency enhances the fractional absorption
of aluminum [49]. This assumption is deduced from several
observations. (a) Clinical studies reported a negative relationship
between serum ferritin and serum aluminum concentrations in
dialysis patients [28—30]. (b) One uncontrolled study found ele-
vated urinary excretion rates of aluminum in renal failure patients
with low serum ferritin, suggesting increased intestinal absorption
[31. (c) As it was the case in other cell lines, the rat intestinal cell
line RIE1 takes up aluminum via the transferrin receptor and iron
deficiency enhances this uptake [18, 24]. (d) A recent animal
experiment claimed to provide evidence for a clear-cut relation-
ship between iron deficiency and enhanced aluminum absorption
[18]. However, each of these lines of evidence has its obvious
shortcomings, and on the basis of the experimental data provided
by the present study the effect of iron status on the intestinal
absorption of aluminum needs a reappraisal. In particular, our
study challenges many, if not all, of the previously published
experimental data suggesting that iron-deficient rats reproducibly
absorb more aluminum than do iron-replete controls [18]. As
regards the clinical studies a negative correlation between the
serum concentrations of ferritin and aluminum could also be
explained by the fact that the degree of iron saturation may affect
aluminum binding to transferrin. Support for this alternative
explanation stems from experimental data of D'Haese et al, who
demonstrated that a gradual increase in iron-transferrin satura-
tion caused a progressive decrease not only in free binding sites
available for aluminum, but also in the affinity of apotransferrin
for aluminum [50]. In addition, since the increment in serum
aluminum following a desferrioxamine test did not correlate with
serum ferritin in the study of Huang et al, there was no evidence
that the tissue burden of aluminum was more elevated in iron-
deficient patients [28]. Moreover, other clinical investigations that
addressed the effect of body iron stores on the intestinal absorp-
tion of aluminum more directly have yielded conflicting results
[11]. While one study in dialysis patients demonstrated a negative
correlation between serum iron concentration and the increment
in serum aluminum after an oral aluminum load [30], another
report indicated that simultaneous administration of iron supple-
mentation together with aluminum-containing phosphate binders
tended to enhance rather than to decrease aluminum absorption
[31]. In the study that reported a larger urinary excretion of
aluminum in renal failure patients with low serum ferritin the
increase was small and differences in the dietary aluminum load
were not assessed [331.
The data of the present study strongly argue against the
hypothesis that iron deficiency causes hyperabsorption of alumi-
num. To make sure that our negative findings were correct, we
carried out several independent series of experiments using
different animal models comprising different doses of aluminum,
variable durations of exposure to aluminum and various alumi-
num compounds. On purpose, we did not study citrate-containing
diets despite the fact that citrate is an important determinant of
the intestinal absorption of aluminum and that dietary constitu-
ents such as citrate have to he considered [11]. Citrate increases
the intestinal absorption via the paracellular pathway, and this
process is not likely to involve iron-specific carriers [141. However,
12000
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Time, minutes
Fig. 6. Semm aluminum (Al) concentrations in uremic rats (Nx) during in
situ small intestinal peifusion with an Al-containing perfusion solution with or
without kinetin added and in appropriate controls (C) with normal renal
ftmction (N = 6per group) (mean Sc). *p < 0.01 versus Nx, • denotes
P < 0.05 versus respective controls. Serum aluminum concentrations at
minutes 30 to 75 were significantly different from respective baseline
values (P < 0.01). Symbols are: —•—, C; --A--, Nx + kinetin; —0—, Nx;
--X--, C+ kinetin.
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besides citrate there are other complexing agents in the diet that
increase the intestinal absorption of aluminum that may not affect
the permeability of the paracellular pathway [16]. Our earlier
studies demonstrated that lactate is one of them [17] and,
consequently, we chose lactate rather than citrate in two of our
experiments. Finally, a recent study that reported enhanced
absorption of aluminum in iron-deficient rats used aluminum
hydroxide and aluminum chloride but not citrate to dose the
animals [18]. Each group of our three different experimental
models had a well-defined body iron status. Measurement of
nonheme iron concentrations in liver and in intestinal mucosa
clearly confirmed marked alterations of body iron stores in the
respective groups. However, neither single dose studies nor an
extended exposure to dietary aluminum supported a role for iron
status as an important modulator of aluminum absorption.
Following a single oral dose of aluminum chloride neither the
post-load increment in serum aluminum nor urinary excretion
rates of aluminum differed between iron-overloaded rats, iron-
deficient animals and iron-replete controls with comparable renal
function. The same findings applied to the increment in serum
aluminum during in situ intestinal perfusion with aluminum
lactate-containing perfusate. Again, the kinetics of serum alumi-
num were remarkably comparable between the three study
groups. To exclude that the observed time course of post-load
serum and urine aluminum was confounded by iron-related
differences in compartmentalization or renal handling of alumi-
num, an intravenous aluminum dose was administered in separate
experiments. Irrespective of iron status intravenous delivery of
aluminum yielded similar cumulative excretion rates in control
and treatment groups with intact kidneys, suggesting that interac-
tion of iron and aluminum had not disturbed the interpretation of
the urinary excretion rates of aluminum. In iron-overloaded
uremic rats, however, urinary recovery of aluminum was signifi-
cantly reduced as compared to group Nx+Fe—. If anything,
measurement of urine aluminum may underestimate fractional
absorption of aluminum in the presence of iron overload and
uremia. This particular phenomenon may have led to the errone-
ous conclusion of hyperabsorption of aluminum in iron deficiency
as compared to iron overload and may thus have contributed to
contradictory data in the past [18, 32, 33].
The findings of our short-term single dose experiments apply
also to a prolonged dietary exposure to aluminum over 41 days. As
has been observed previously by other investigators [51], this
maneuver resulted in an increase in bone aluminum as well as in
aluminum concentrations in liver and spleen, indicating that these
organs are the major sites of aluminum storage [1, 52]. Again, we
could not provide any evidence that iron deficiency had increased
aluminum absorption. The increase in bone aluminum was com-
parable among groups with similar renal function and spleen
aluminum was even larger in iron-overloaded rats. Serum and
urinary aluminum did not differ among groups with similar renal
function and, what may be of particular interest, iron deficiency
was not associated with excessive accumulation of aluminum in
brain. Our data are in line with a previous investigation that
showed no effect of iron deficiency on blood or liver aluminum
concentrations in rats fed aluminum-rich tea leaves [32], and our
findings are at odds with a report indicating that iron deficiency
enhances aluminum absorption and deposition in brain [18].
However, the latter study did not report aluminum concentrations
in the target organs bone, liver, and spleen where the major
fraction of a systemic aluminum burden is deposited, and mea-
surements of low levels of brain aluminum is subject to many
analytical problems [1, 39].
Our findings contrast with recent evidence that iron deficiency
enhances the cellular uptake of transferrin-bound aluminum by a
rat intestinal epithelial cell line [24]. Therefore, it was suggested
that transferrin should mediate the absorption of aluminum and
that increased expression of intestinal transferrin receptors should
lead to increased aluminum absorption in iron deficiency [24, 49].
However, the relevance of transferrin receptor-mediated uptake
of aluminum for the intestinal absorption process is questionable.
In intestinal epithelial cells transferrin receptors are not expressed
at the apical surface and are thus not available to intraluminal
aluminum [25, 26, 53, 54]. Consequently, recent studies have
shown that transferrin is unlikely to be the mucosal regulator of
iron absorption [53, 54, 55]. Therefore, individuals with atransfer-
rinemia have increased rather than decreased total body iron
stores [56}, and the gene for transférrin is not expressed in
duodenal mucosal cells [57, 58]. Instead, it appears that iron
uptake from the gut is facilitated by a transferrin-independent
transport system utilizing 3 integrin and mobilferrin, a homo-
logue of caireticulin [55, 59—61]. Although these proteins may
also bind zinc, cobalt, and lead, their interaction with aluminum
remains speculative and needs to be investigated [53]. In the
present study peroral co-administration of aluminum and iron did
not reduce, but tended to enhance aluminum absorption. This
seems to argue against competitive binding to, and apical alumi-
num uptake by these iron-specific carriers. In addition, when we
measured mucosal aluminum concentrations, there was an in-
crease five hours post-load that persisted in uremic animals, but
this increment was not augmented by iron deficiency. If anything,
mucosal aluminum concentrations tended to be higher in iron-
overloaded uremic rats after 24 hours. Our data are in line with
recent findings demonstrating that in mucosal cytosol extracts
aluminum may associate with two proteins, neither of which bind
iron [62].
The present study confirms that the intestinal absorption of
aluminum is enhanced in the uremic state. This has been a
consistent phenomenon in a series of previous experiments,
however, the cause of this impaired barrier function of the
intestine has not been fully elucidated [11, 15, 17, 63, 64]. The
magnitude of aluminum absorption in the remnant kidney rat
model is positively correlated with severity and duration of renal
failure, but enhanced absorption cannot be attributed to the
degree of hyperparathyroidism, to calcitriol deficiency or to
changes in gastric acid secretion [11]. This study clearly demon-
strates that the increase in aluminum absorption in uremia is not
related to subtle or overt iron deficiency since uremic rats had
similar liver iron concentrations as compared to controls, Instead,
our data are compatible with the notion that the increase in the
fractional absorption of aluminum may be related to enhanced
paracellular permeability of the intestine. Evaluation of intestinal
permeability in rats by other investigators has indicated reduced
permeability in acute renal failure and increased permeability in
chronic renal failure [65, 66]. Morphological and functional
alterations of the small intestine in uremia are well established
[67—69], and these changes may be involved in the pathogenesis of
disturbed paracellular permeability. We noted increased intestinal
mannitol absorption in uremic rats suggesting a substantial para-
cellular shunt pathway irrespective of iron status. Blockade of
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paracellular permeability by means of kinetin resulted in a
blunted increase in serum aluminum concentrations during intes-
tinal perfusion with aluminum lactate consistent with the view that
excess absorption in uremia had occurred via the transepithelial,
extracellular pathway. Since kinetin did not completely normalize
the time course of serum aluminum as compared to controls,
additional, noniron-dependent transcellular mechanisms may be
operating as well to facilitate aluminum absorption in renal
failure. It is noteworthy that kinetin did not reduce the time-
dependent increment in serum aluminum in controls. Given the
low intestinal permeability in the presence of normal renal
function, this would imply that the usual site of aluminum
absorption is via the transcellular pathway. Exceptional transepi-
thelial movement of aluminum along the paracellular pathway has
only been demonstrated following administration of citrate due to
chelation of calcium and subsequent opening of cellular tight
junctions [14]. Apparently, uremic enteropathy may constitute
another condition where epithelial leackage allows paracellular
aluminum permeation across the intestinal barrier.
In conclusion, the present study provides several lines of
evidence against the previously held view that intestinal absorp-
tion of aluminum occurs via iron-specific or via transferrin-
dependent pathways. This negative finding may be related to the
neglected fact that transferrin receptors are not expressed on the
absorptive surface of intestinal cpithelial cells and that absorption
of iron is instead facilitated by the mucin-mobilferrin-integrin
pathway. In addition, changes in body iron status do not affect the
enhanced aluminum absorption in the uremic state. This phenom-
enon is in part due to increased paracellular permeability. Further
clinical and experimental studies using the isotope 26A1 in con-
junction with accelerator mass spectrometry are needed to con-
firm these observations [701.
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